Plus   Neg

J. M. Smucker Lifts FY Outlook

J. M. Smucker Co. (SJM) on Monday raised its full-year earnings and revenues outlook driven largely by "unprecedented" demand for its food products reflecting stocking up by customers due to ongoing stay-at-home orders enforced to curb the coronavirus pandemic.

Orrville, Ohio-based J.M. Smucker now expects adjusted earnings to exceed the high end of its previous forecast range of $8.10 to $8.30 per share.

The company now expects sales to fall 1% in the fiscal year ending April 30, 2020, compared to its prior forecast for a drop of 3%.

"Unprecedented customer and consumer demand in the company's fourth quarter has improved its fiscal year financial expectations. The anticipated improvement will benefit both GAAP and non-GAAP results," the company said in a statement.

SJM closed Monday's trading at $121.62, up $0.04 or 0.03%, on the NYSE. The stock further gained $1.62 or 1.33% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT